InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, and talks about whether the industry is ready for synthesized cannabinoids.
Read the article and watch the full video at The Dales Report.
InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, and talks about whether the industry is ready for synthesized cannabinoids.
Read the article and watch the full video at The Dales Report.
In this article, read about the prevalence of age-related macular degeneration and InMed’s promising preclinical studies of INM-089, a small molecule drug candidate in development
In this short video, InMed’s CEO, Eric A. Adams, provides a summary of the preclinical studies of INM-901, the company’s drug candidate in the potential
In this Fierce Biotech article, we learn about how the preclinical results of INM-901 indicate that this drug candidate may address multiple pathologies related to
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields